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Abstract
Synonymous variations, which are defined as codon substitutions that do not change the encoded amino acid, were
previously thought to have no effect on the properties of the synthesized protein(s). However, mounting evidence shows
that these ‘‘silent’’ variations can have a significant impact on protein expression and function and should no longer be
considered ‘‘silent’’. Here, the effects of six synonymous and six non-synonymous variations, previously found in the gene of
ADAMTS13, the von Willebrand Factor (VWF) cleaving hemostatic protease, have been investigated using a variety of
approaches. The ADAMTS13 mRNA and protein expression levels, as well as the conformation and activity of the variants
have been compared to that of wild-type ADAMTS13. Interestingly, not only the non-synonymous variants but also the
synonymous variants have been found to change the protein expression levels, conformation and function. Bioinformatic
analysis of ADAMTS13 mRNA structure, amino acid conservation and codon usage allowed us to establish correlations
between mRNA stability, RSCU, and intracellular protein expression. This study demonstrates that variants and more
specifically, synonymous variants can have a substantial and definite effect on ADAMTS13 function and that bioinformatic
analysis may allow development of predictive tools to identify variants that will have significant effects on the encoded
protein.
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Introduction
ADAMTS13 (A Disintegrin-like and Metalloprotease with
Thrombospondin type-1 repeats, member-13) plays an integral
role in vascular hemostasis by cleaving von Willebrand Factor
(VWF) within intact blood vessels under shear stress [1]. At sites of
vascular injury, VWF binds to the sub-endothelium and tethers
platelets to this site, initiating coagulation. A deficiency in
ADAMTS13 activity – either through inactivation by autoanti-
bodies, lack of expression, or a genetic variation affecting function
(these primarily include single site codon substitutions) – results in
increased VWF thrombogenic potential. Extreme cases of
ADAMTS13 deficiency precipitate Thrombotic Thrombocytope-
nic Purpura (TTP [OMIM 274150] - http://www.omim.org/),
a life threatening hematological disease [2].
Single nucleotide polymorphisms (SNPs), originally defined as
single site codon substitutions that occur in .1% of the
population, are prevalent and are found across the entire human
genome coding sequence, with few exceptions. Approximately
962,258 unique SNPs have been reported in the coding sequence
of the human genome, although frequency data are not available
for all of these SNPs. Therefore, SNPs are now classified as
genomic variants and it is no longer possible to distinguish
between SNPs and mutations based on their frequency [3].
Mounting evidence suggests that these synonymous (‘‘silent’’)
variants may impact protein expression and function [4–10]. In
humans, synonymous variants have been shown to affect mRNA
splicing [5], mRNA stability [11] and/or mRNA secondary
structure [12–15], translation efficiency and kinetics [16,17],
protein folding [10,18,19], and protein function [18].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38864At the inception of this project, we chose to investigate twelve
ADAMTS13 variants – six synonymous variants and six non-
synonymous variants (the latter defined as single site codon
substitutions that do change the encoded amino acid) and
originally listed in the coding region of the gene in the NCBI
dbSNP (http://www.ncbi.nlm.nih.gov/snp, last accessed 24
October 2011). Some of these variants have been previously
investigated using in vitro methods by other researchers [20–23].
One hundred and thirty more variants have been added to dbSNP
recently, probably as a result of the increased population
sequencing from the 1000 Genomes Project. These variants are
not subjects of the current study; however, we do plan to include
them in future analyses.
Here, we have used a transient expression system to study the
effects of the twelve variants mentioned above on mRNA and
protein expression levels, protein activity and conformation ex vivo,
in cells. In addition, we have employed a variety of computational
methods to analyze the potential effects of these variants on
ADAMTS13 mRNA splicing, change in mRNA structure, codon
usage and amino acid conservation as well as the relationships
between the location of these variants in the encoded polypeptide
chain and the wild-type (WT) ADAMTS13 (predicted) protein
structure.
Substantial differences in protein expression levels, activity and
conformation were found between WT ADAMTS13 and
ADAMTS13 variants, suggesting that both non-synonymous and
synonymous variants in ADAMTS13 are not neutral. Furthermore,
we demonstrate that in silico analysis may serve as a tool to identify
variants that may potentially have an effect on the protein bearing
them, altering its expression levels and/or activity. In silico
variables with high correlation to ex vivo results (Spearman’s
rho$0.6; p-value,0.05) may become important for the charac-
terization of potential TTP patients carrying genetic variants.
These in silico variables may also be used in the future for
developing safer and more effective therapeutic recombinant
proteins. This may be achieved by taking into account the
predicted effects of variants (and even haplotypes) on ADAMTS13
or any other therapeutic recombinant protein characteristics.
Results
Computational Prediction of mRNA Structure/Stability
and Analysis of ADAMTS13 mRNA Expression Levels
Drawing on many previous reports that analyzed the local
secondary structure of mRNA, we used mFold [24], a static
secondary structure predictor, and KineFold [25], a stochastic
secondary structure predictor, to analyze potential changes in the
minimum free energy (DG) of the mRNA fragments harboring
variants under investigation. The DDG (variant DG minus WT
DG) was calculated for mRNA fragments of different lengths (25,
75, 151 and 399 nucleotides), with the variant of interest
positioned in the middle of the mRNA fragment analyzed. We
have limited our analysis to RNA fragments/lengths described
above, as it is currently unfeasible to predict with sufficient
accuracy the structure/stability of longer RNA fragments, as the
number of possible structures grows exponentially with the
sequence length [24]. The absolute DDG values calculated for
a given variant by different software programs and for RNA
fragments of different lengths as well as their associated trends
were not always in agreement with each other, potentially
reflecting the exceptional plasticity of RNA, as well as known
limitations of the software packages used, e.g. only KineFold is able
to predict pseudoknots (Figure 1AB). Nevertheless, synonymous
variant 354, independently of the length of the RNA fragment
analyzed, was predicted (using both programs) to affect RNA
stability to a similar extent (although the absolute magnitude of the
effects differed for the two programs used), while synonymous
variant 420 showed considerably different DDG values and trends
associated with RNA fragments of different lengths (Figure 1AB).
Overall, the highest DDG calculated by mFold was observed for
synonymous variant 4221 (for a fragment of 75 nucleotides in
length) and the lowest DDG was observed for synonymous variant
420 (for a fragment of 151 nucleotides in length) (Figure 1A). At
the same time, the highest DDG calculated by KineFold was
observed for non-synonymous variant 1451 (for a fragment of 399
nucleotides in length) and the lowest DDG was observed for
synonymous variant 1716 (for a fragment of 399 nucleotides in
length) (Figure 1B). Although, analysis of mRNA structure within
the coding region is admittedly a yet-to-be developed research
area, the predicted changes in DDGs may lead to change in
mRNA stability and/or protein expression levels.
In order to test whether there might be any association between
the predicted changes in mRNA stability and mRNA expression
levels, we performed qPCR to determine ADAMTS13 mRNA
expression levels in transfected cells. mRNA levels were monitored
24 hours (h.) post-transfection. Significant differences in
ADAMTS13 mRNA levels between cells transfected with a plasmid
harboring WT ADAMTS13 gene and those transfected with
ADAMTS13 variants were observed for variants 1451, 1716, and
2699 (p-value ,0.02, 0.02, 0.04 by 2-sided t test, respectively)
(Figure 1C). On average, the change in mRNA expression levels
was not more than 50% of WT (Figure 1C) for the majority of
variants under investigation. One of the largest changes, was found
for non-synonymous variant 1451, and remained only 191611%
of WT. Additionally, we observed a correlation (Spearman’s
rho=20.62, p-value,0.03) between the mRNA levels (Figure 1C)
and their predicted free energies as calculated by KineFold for
a nucleotide length of 25 (Figure 1B).
Computational Analysis of Codon Usage
While several codons may encode a single amino acid due to
general degeneracy of the genetic code, not all codons occur at the
same frequency throughout the genome and a strong codon bias
exists [26]. Moreover, different organisms have distinct codon
biases [26] and it is possible that there may be differences in codon
biases between tissues within the same organism [27–31],
reflecting tissue specificity in gene expression. More importantly
for the present study, changes in codon frequencies (in addition to
the changes in RNA structure) have been shown to affect the local
speed of translation and this can also impact co-translational
protein folding and result in a protein with different conforma-
tion/specific activity [18,19,32]. It is believed that the overall
impact of a given codon change on the rate of translation and co-
translational protein folding would be more detrimental in the case
that it would cause a more substantial change in the codon usage
frequency [18,19,32]. We therefore compared the codon usage
frequencies of each individual variant versus WT codon at the
same position using two different approaches (see Materials and
Methods for details). In brief, the differences between a variant’s
codon usage and the corresponding WT codon usage were
calculated using either the Relative Synonymous Codon Usage
(RSCU) values [33] or the log ratio of the human codon usage
frequencies and the codon usage frequencies of ADAMTS13, and
are shown in Figures 1D and 1E, respectively. The twelve variants
studied here were chosen at random and the DRSCU and Dlog
ratio scores of all twelve fall within the distribution of DRSCU and
Dlog ratio scores of all synonymous and non-synonymous variants
in ADAMTS13 (Figure 1F).
Synonymous and Non-Synonymous Variants in ADAMTS13
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38864The most substantial change in the log ratio of codon usage
frequencies from variant to WT codon as well as the highest
DRSCU was observed for non-synonymous variant 2699
(Figures 1D and 1E). Three of the largest increases in the Dlog
ratio of codon frequency and DRSCU, regardless of the analysis
method used, are for synonymous variants –354, 420 and 2280–
demonstrating that the WT codon in each of the above mentioned
cases is rarer than the variant codon. Additionally, five variants
revealed different changes in their log ratio of codon frequencies
based on genomic and ADAMT13 codon frequencies: non-
synonymous variants 1423, 1451 and 3097 and synonymous
variants 2910 and 4221. The most noticeable difference between
ADAMTS13 and genomic codon frequencies was observed for
non-synonymous variant 1451 in which ADAMTS13 absolute Dlog
ratio of codon frequency is roughly 16% of the genomic Dlog ratio
of codon frequency (Figure 1E), suggesting that the AAA codon
Figure 1. Analysis of mRNA structure/stability, codon usage and expression levels of ADAMTS13 variants: A. mFold DDG values of
ADAMTS13 mRNA fragments: RNA fragments of 25, 75, 151, and 399 nucleotides in length were queried using online mFold server, utilizing default
server settings. Variants were centered within the RNA fragments used in the analysis. The most stable structures (lowest DG) for both variant and WT
ADAMTS13 variants were chosen. DDG( DG variant - DG WT) was calculated and is displayed here for each of the variants. B. KineFold DDG values
calculated using online KineFold server (obtained employing a similar strategy). C. ADAMTS13 mRNA expression levels as determined by qPCR:
Analysis of mRNA expression was performed 24 h. post-transfection with quantitative real time PCR on WT ADAMTS13 and all twelve variants. GAPDH
was used as a reference and a DDCp was calculated using the average of all WT DCp results for comparison. Fold change relative to WT is presented
on a logarithmic scale. mRNA expression levels were analyzed in multiple independent transfection experiments utilizing each variant and WT
ADAMTS13 variant, and found to be consistently similar from one experiment to the another (**p-value ,0.05). D. Differences in Relative
Synonymous Codon Usage (RSCU) values between each of the ADAMTS13 variant codons and the WT codon: DRSCU= D(RSCUVariant – RSCUWT);
the more positive is the DRSCU value, the more common is the variant codon compared to WT codon. RSCU values were calculated using the
ADAMTS13 coding region and human codon usage information. E. Differences between log ratio of codon usage values for each of the ADAMTS13
variants and WT. The plotted values are the differences between log ratio of codon usage frequency of the variant and WT codon (D(variant – WT)).
The more positive the delta, the more commonly used the variant codon is, compared to WT. Values were calculated using the ADAMTS13 coding
region and human codon usage information. F. Normal distribution of RSCU values for all variants in ADAMTS13: The RSCU and log ratio of codon
usage values were determined for all variants in the coding region of ADAMTS13. MAD scores were assigned to the DRSCU and Dlog ratio of all
variants. Comparison of MAD scores of twelve variants and all variants in ADAMTS13 revealed that DRSCU and Dlog ratio scores for the twelve variants
fell within the distribution of variants in ADAMTS13. ADAMTS13 variants harboring synonymous variants are marked with (*).
doi:10.1371/journal.pone.0038864.g001
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sequence in comparison with the entire ORFeome.
Changes in Protein Expression of ADAMTS13
Immunoblot analysis against the linear V5 epitope (at the C-
terminus of ADAMTS13) was used to determine the effect of each
variant on the expression of the mutant proteins as compared to
the WT ADAMTS13. Both intra- and extra-cellular ADAMTS13
expression levels were determined. Transient transfections with
WT ADAMTS13 construct were performed in triplicate and the
resulting protein expression levels were measured at a range of
total protein concentrations (loaded on a gel) to ensure that final
measurements were done within the region of linear response
(Figure 2A). Based on these data, 40 mg of total protein was
selected as the optimal loading amount to establish the assay. Our
results were linear within 95% confidence limits (Figure 2A). It
should also be noted that trends in expression levels of
ADAMTS13 constructs harboring the same variant were similar
for all experiments done in parallel. Densitometry analyses of the
band intensities of WT and variant-containing ADAMTS13
samples were performed and presented as a percent of WT,
where WT expression level was set to 100%.
Cells expressing ADAMTS13 non-synonymous variant 3097
revealed the highest increase in extracellular ADAMTS13
expression of 179635% of WT (p-value=0.06 by 2-sided t test)
(Figure 2B). ADAMTS13 constructs with synonymous variants 354
and 420 showed the second and third highest respective increases
in extracellular expression levels as compared to WT (137617%,
p-value,0.06 and 120626%, of WT, p-value=0.3 by 2-sided t
test, respectively). The non-synonymous variant 1852 showed
a significant decrease, resulting in less than a third (3163%, p-
value,0.0007 by 2-sided t test) of the extracellular WT expression
level. As both intracellular and secreted proteins represent the
active forms of ADAMTS13 [34], we have also compared the
levels of intracellular ADAMTS13 (Figure 2C). The non-
synonymous variants 1451 and 2699 and synonymous variant
1716 ADAMTS13 variants showed decreased intracellular
expression compared to WT (4865% p-value,0.003, 29613%
p-value,0.002 and 8267% of WT p-value=0.04 by 2-sided t
test, respectively), while non-synonymous variants 1342 (p-
value,0.05 by 2-sided t test) and 1423 ADAMTS13 variants (p-
value,0.02 by 2-sided t test) showed increased (41% and 30%,
respectively) intracellular expression compared to WT. In lieu of
an increase in extracellular expression above WT, the
ADAMTS13 construct harboring synonymous variant 354 also
revealed a 146621% (p-value=0.06 by 2-sided t test) increase in
intracellular expression above WT.
ADAMTS13 variants did not show any significant correlation
between intra- and extracellular expression (Spearman’s
rho=0.98, p-value.0.7). Mutants highly expressed in the in-
tracellular compartment were not necessarily highly secreted and
vice versa. A representative example, in which three independently
transfected ADAMTS13 constructs (WT, non-synonymous var-
iants 1451 and 1852) were simultaneously analyzed, is shown in
Figure 2D. The ADAMTS13 non-synonymous 1451 variant
showed decreased intracellular expression levels compared to WT
and unaffected extracellular levels (compared to WT), while the
ADAMTS13 non-synonymous variant 1852 variant showed the
opposite trend. These results indicate that various ADAMTS13
variants may have different effects on intracellular and extracel-
lular protein expression and these two parameters may not
necessarily correlate. These differences in intra- and extracellular
expression levels may result from the conformational changes
between the ADAMTS13 variants that differentially facilitate or
impede their travel through certain intracellular compartments,
and/or subject them to enhanced degradation.
We found that changes in intracellular ADAMTS13 expression
levels correlated strongly (Spearman’s rho=0.67, p-value=0.02)
with corresponding changes in RSCU values calculated using
human codon frequencies. In addition, changes in mRNA
minimum free energy values (DDGs based on KineFold predic-
tions for the 175 nucleotide fragment (Spearman’s rho=0.69, p-
value=0.012)) unexpectedly correlated with the corresponding
changes in ADAMTS13 extracellular expression levels. We found
no correlation between ADAMTS13 mRNA levels and either
extracellular protein expression (Spearman’s rho=0.20, p-val-
ue=0.40) or intracellular protein expression levels (Spearman’s
rho=20.29, p-value=0.35).
ADAMTS13 Variants Show Differences in Specific Activity
Activity of each ADAMTS13 variant was determined (and
compared to that of the WT protein) using the FRETS-VWF73
fluorogenic substrate and normalized to extracellular ADAMTS13
expression levels to yield the specific activity (Figure 3A). Un-
expectedly, two ADAMTS13 synonymous variants, 354 and 2280,
demonstrated the highest specific activity (207677% and
181641%, respectively) compared to WT. Statistical analysis
demonstrated that these differences in specific activity were not
significant (p-value,0.1 and 0.2 by 2-sided t test, respectively). At
the same time non-synonymous variants 1451 and 1423 were
found to have the lowest specific activity (5668% with p-
value,0.01 and 5865% with p-value,0.006 by 2-sided t test,
respectively). We further chose to investigate the non-synonymous
2699 variant (which revealed a ,25% decrease in specific activity)
because the ADAMTS13 protein bearing this variant revealed the
lowest intracellular expression level compared to WT protein, with
no change in extracellular protein expression levels compared to
WT. This suggests possible conformation changes within the
mutant protein that perhaps might lead to enhanced intracellular
degradation of non-synonymous variant 2699 species that do not
pass quality control mechanisms in the ER. However this protein
might also travel faster through the secretory pathway and thus the
total amount of the extracellular protein may remain unchanged.
In order to detect any minor changes in conformation between
2699 and WT, a more detailed kinetic analysis was performed in
the case of non-synonymous variant 2699 and WT (Figure 3B,
middle panels). Vmax (RFU min
21) and KM (mM) for WT
ADAMTS13 and non-synonymous variant 2699 mediated cleav-
age of the fluorogenic substrate FRETS-VWF73 are shown in
Figure 3B. These data revealed an approximately 2-fold difference
estimated in Km and Vmax values between the intracellular forms
of the non-synonymous variant 2699 and WT proteins, re-
spectively. Thus, our analysis of the specific activity of 12
ADAMTS13 variants and the detailed kinetic analysis of non-
synonymous variant 2699 clearly demonstrated differences in
specific activity as compared to WT.
Limited Trypsin Digestion Suggests that ADAMTS13
Variants may have Different Conformations
To probe and compare the conformations of the variant
ADAMTS13 proteins, we subjected them to limited proteolysis
with trypsin. We specifically chose to investigate non-synonymous
variant 1852, because this ADAMTS13 variant revealed the
lowest extracellular expression levels and reduced specific activity
as compared to the WT protein. We hypothesized that the
differences in expression and function may result from conforma-
tional changes within the protein. Increased resistance to limited
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38864Figure 2. Ex vivo analysis of expression levels of ADAMTS13 variants. A. Western blotting data revealing linear dependence between the
amount of the loaded protein and the western signal: Media was collected and concentrated 24 h. post-transfection. Increasing amounts of total
protein (5, 10, 20, 40, 60 and 80 mg) were subjected to SDS-PAGE analysis. Anti-V5 antibody was used to detect ADAMTS13 and densitometry analysis
was performed as described in Materials and Methods. The dashed bolded lines indicate 95% confidence limits and the dashed non-bolded lines
represent 90% confidence limits. B. Extracellular ADAMTS13 Expression (based on immunoblot analysis). Expression results for each variant are
presented relative to WT. Multiple independent transfection experiments utilizing each variant and WT ADAMTS13 construct were performed (**p-
value ,0.05). C. Intracellular ADAMTS13 Expression (based on immunoblot analysis): GAPDH and/or b-actin were used as loading controls (not
shown). Expression results for each variants are presented relative to WT. Multiple independent transfection experiments utilizing each variant and
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1852, as compared to WT (Figure 3C).
Analysis of ADAMTS13 Structure and Locations of
Variants
It has been suggested that not every non-synonymous or
synonymous codon substitution would have an equal impact on
protein folding in the cell [17]. The impact of any given variants
on the folding of any given protein was suggested to be dependent
on the effects produced by variants on the stability and structure of
the folding intermediates forming along the co-translational
folding pathway [17]. Substitutions that affect codons encoding
structurally important residues and/or protein fragments (e.g.
domain linkers) were suggested to elicit more substantial effects on
protein folding in comparison with other non-synonymous or
synonymous variants [17]. Therefore, we have attempted to
predict and analyze the structure of the ADAMTS13 protein and
locate the residues encoded by codons/variants under investiga-
tion onto the predicted structure (Figure 4, Table 1). Although
prediction of the protein structure is yet a very challenging task
and cannot be considered proof that the predicted structures will
form, we believe that this prediction can be taken into account
with certain level of precaution. Comparative modeling of the
ADAMTS13 structure using the 3D-PSSM algorithm [35] yielded
two protein fragments (comprising residues 77–470 and 674–1254
respectively) and allowed us to conclude that variants under
investigation might affect residues located at the edges of the
secondary structures (most likely beta-structures) (Figure 4, top two
panels; Table 1). It should also be noted that the structure of the
ADAMTS13 fragment (comprising residues 287–682) has been
recently solved by X-ray crystallography (PDB ID 3GHM) and
thus we were able to extend our analysis onto this fragment (which
was not covered by in silico predictions). Similar to in silico findings,
4 out 5 variants in the ADAMTS13 (287–682) X-ray fragment
encode residues located in beta-structures (Pro475 (ADAMTS13
variant 1423), Arg484 (ADAMTS13 variant 1451), Thr572
(ADAMTS13 variant 1716) and Pro618 (ADAMTS13 variant
1852), respectively) with 2 (ADAMTS13 variants 1451 and 1852)
located at the very edges of the secondary structures (Figure 4,
bottom panel; Table 1). This observation complements our in silico
predictions.
Analysis of Conservation of Residues Associated with
ADAMTS13 Variants
An interesting question to consider is whether ADAMTS13
variants under investigation are found at codons that encode in
WT ADAMTS13 evolutionary conserved amino acid residues.
One would expect that non-synonymous variants will be found at
less conserved residues, as variants at conserved residues are
expected to severely affect protein function, while synonymous
variants, should, in principal, be subjected to less evolutionary
pressure. To answer this question, we have determined the
conservation of the ADAMTS13 amino acid residues using
sequence alignments of 50 homologues proteins from Swissprot
database (http://www.uniprot.org/, last accessed 7 June 2011)
and by employing the ConSeq server [36]. The ConSeq server
scores the conservation of amino acids from 1 (not conserved) to 9
(most conserved). Overall, as shown in Table 2, the conservation
of the 12 residues under investigation was relatively low, albeit on
average ranging from not conserved to moderately conserved
(Table 2). The highest conservation was observed for Thr1407
associated with synonymous variant 4221. Notably, we did not
observe a substantial difference in the conservation values between
synonymous and non-synonymous variants.
Discussion
To our knowledge this is the first study that simultaneously
analyzes a large number of ADAMTS13 variants by employing
a variety of experimental approaches and in silico tools. Our ex vivo
results revealing differences in ADAMT13 expression levels and
activities are fully in agreement with the range of protein activities
observed in healthy individuals (A summary of ex vivo results can be
found in Table S2). For example, Bohm and colleagues [37]
reported similar changes in ADAMTS13 activities up to a 135%
increase or 50% decrease in ADAMTS13 activity, using VWFcp
as measured by the RCo-based assay, and similarly, Zhou and
Tsai [38] reported that ADAMTS13 activity may range from 70%
to 170% in normal individuals. At the same time, Mannucci and
colleagues [39] demonstrated that the expression levels of
ADAMTS13 in individuals of O blood type or non-O blood type,
range from ,35% to ,170%, respectively. However, one should
note that the exact activity level of each ADAMTS13 variant
observed in ex vivo experiments might not precisely correlate with
its activity in plasma. A single variant should not be compared to
a variant coupled with other variants that often appear together as
a frequent haplotype, which may have an alternative significant
effect on hemostasis. Information regarding the frequency of
variants in various populations is not very abundant and the
present study cannot accurately mimic natural ADAMTS13
haplotypes without obtaining additional data that will ultimately
require sequencing of a multitude of patient populations.
However, we believe that the obtained information may yet be
very useful in assessing the effects of individual variants.
Reports in the last five years have indicated that not only non-
synonymous variants, but also synonymous ones, can have
substantial effects on protein expression and function [5,8,40].
Traditionally, recombinant protein therapies and gene therapeu-
tics have introduced variants (most commonly synonymous
variants) in order to facilitate increased protein expression [41].
Similarly, the DNA sequence used in development of recombinant
protein therapeutics sometimes contains one or more variants and
little attention has been previously paid to the effects of such
genetic variants. We believe the results of the present study as well
as the tools and approaches that we have employed and developed
for the analysis of ADAMTS13 variants may be helpful in analyses
of the effects of variants found in other genes/proteins.
The results presented here clearly demonstrate that both non-
synonymous and synonymous variants can affect protein expres-
sion levels and function (Figures 2B, 2C, and 3A). While
highlighting the effects of non-synonymous variants on
ADAMTS13 conformation and activity (Figures 3B and 3C),
our study strongly suggests that the effects of neither non-
synonymous nor synonymous variants should be neglected in any
gene sequence. Importantly, nine of the twelve ADAMTS13
variants under study didn’t have any substantial effect on mRNA
expression levels (Figure 1C), thus suggesting that their effects on
WT ADAMTS13 construct were performed as above (**p-value ,0.05). D. SDS-PAGE immunoblot analysis of ADAMTS13 WT, non-synonymous
variants 1451 (Arg.Lys) and 1852 (Pro.Ala) expression levels using anti-V5 antibody: Top – extracellular ADAMTS13, middle – intracellular
ADAMTS13 and bottom - GAPDH loading control. ADAMTS13 variants harboring synonymous variants are marked with (*).
doi:10.1371/journal.pone.0038864.g002
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38864Figure 3. Specific activity of ADAMTS13 variants and limited proteolysis with trypsin. A. Specific activity of twelve ADAMTS13 variants vs.
WT as determined using FRETS-VWF73 substrate: Samples containing equal amounts of total extracellular protein were incubated with 5 mMo f
FRETS-VWF73 substrate and fluorescence readings were taken at 5 min intervals over the course of 2 h. Specific activity was calculated as the
increase in relative fluorescence units (RFU)/min per unit of ADAMTS13 in the total extracellular protein samples. Extracellular ADAMTS13 protein
amounts were determined using immunoblot analysis with anti-V5 antibody as in Figure 2. ADAMTS13 variants harboring synonymous variants are
marked with (*) (**p-value ,0.05). B. Expression and Michaelis-Menten Kinetics of non-synonymous variant 2699 vs. WT protein: HEK293 cells were
transfected with WT and non-synonymous variant 2699 and harvest 24 h. post-transfection. Samples containing equal total protein amounts, both
intracellular (I) and extracellular (E) (40 mg each), were separated by SDS-PAGE and probed with anti-V5 antibody to determine ADAMTS13
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level. For the constructs that demonstrated significant differences
in mRNA expression levels, i.e. 1451, 1716, and 2699, we found
no corresponding change in extracellular protein expression levels
or specific protein activity. mRNA expression levels of non-
synonymous variants 1451 and 2699 were significantly higher than
that of WT, but this could not account for the differences observed
in protein expression levels, as intracellular protein expression
levels of both variants were found to be significantly lower than
WT and no change in extracellular expression, compared to WT
was observed. Synonymous variant 1716 exhibited significantly
lower mRNA expression levels compared to WT, and this
difference may account for significantly lower intracellular protein
expression levels of this variant compared to WT. However, at the
same time no corresponding change in extracellular protein
expression levels was observed for this synonymous variant as
compared to WT. These findings are consistent with previous
reports indicating that some variants may affect mRNA expression
levels [42]. Further, analysis of the changes in mRNA expression
levels and intra- or extracellular protein expression levels and
expression. Intracellular (N) and extracellular (m) protein samples were incubated with 0–10 mM FRETS-VWF73 substrate. Fluorescence released upon
cleavage was plotted over time, as previously described, and a best-fit linear regression was calculated to determine the initial rate of the reaction.
The change in RFU per unit time was then used to estimate the specific activity of ADAMTS13. Specific activity at each substrate concentration was
plotted and a Michaelis-Menten plot was generated using GraphPad Prism software to calculate KM and Vmax values. C. Limited Trypsin digestion of
ADAMTS13 variants: Resistance of the intracellular full-length ADAMTS13 non-synonymous variant 1852 (m) was compared to that of WT (&) using
densitometry analysis of the immunoblot data, as described the Materials and Methods. Non-synonymous variant 1852 revealed increase resistance to
trypsin digestion compared to WT.
doi:10.1371/journal.pone.0038864.g003
Figure 4. Ribbon diagrams of the ADAMTS13 fragments. Two upper panels: Left - comprising residues (77–470) and right (674–1254) built
using comparative modeling (3D-PSSM algorithm). Bottom panel ADAMTS13 X-ray structure residues (287–682) PDB ID 3GHM. Helices are depicted in
red and beta-structures are in yellow. Residues encoded by codons/variants under investigation are denoted with residue number (van der Waals’
radii of the side chains are shown). Beginning and end of each fragment are also denoted with a residue number.
doi:10.1371/journal.pone.0038864.g004
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that in higher eukaryotes only a small fraction of the changes at the
proteome level is directly reflected by the changes at the
transcriptome level [43] thus highlighting an important role
played by the translation and post-translational controls of gene
expression. Yet, the possibility that changes in protein expression
levels observed in the present study may also arise as a result of
alternative mRNA splicing [34] could not be completely ruled out.
However, putative alternative splicing would not affect mRNA
levels, but might impact efficiency of translation. Computational
analysis done in the present study using a variety of approaches
[44–47] indicated that this scenario is very unlikely. No novel
splice sites were predicted to arise in ADAMTS13 mRNA due to
variants under investigation (Table S1).
Therefore, the reported changes in protein expression levels are
very likely to arise at the post-transcriptional level. Changes in
mRNA structure/folding and minimum free energy may represent
one of the reasons for altered protein production. Interestingly, we
found a negative correlation between the DDG values of the
mRNA 175-nucleotide fragments harboring ADAMTS13 variants
(when calculated using KineFold, Figure 1B) and extracellular
ADAMT13 protein expression levels (Figure 2B). This negative
correlation is rather unexpected, since one would normally expect
the opposite–RNA structures with higher minimum free energies
are expected to impede efficient protein translation, while lower
minimum free energies are predicted to facilitate it. While these
results may yet suggest that changes in the predicted minimum
free energy of mRNA within the coding sequence may reflect
protein expression levels, they may also underline the importance
of post-translational events in the secretory pathway that alter the
amount of the final secreted product. It should also be mentioned
that eukaryotic mRNAs do not exist in cells as naked polynucleo-
tides, but rather are represented by messenger ribonucleoprotein
complexes mRNPs [48]. It was shown that mRNA binding
proteins may affect almost every aspect of mRNP metabolism
from transport to localization, translation and turnover [48].
Variants may produce changes in the mRNA sequence/structure
affecting its association with specific proteins and thus altering the
fate of the encode protein. However, such effects are extremely
difficult to predict. It is important to note that we did not observe
any correlation between DDG mRNA values and the changes in
intracellular protein expression levels (Figure 2C) (Spearman’s
rho=0.02, p-value=0.96), further suggesting that the observed
relationship between changes in mRNA minimum free energy and
extracellular protein expression is likely due to the secondary
effects perhaps related to the altered protein conformation and
stability rather than to the direct effects related to the efficiency of
protein translation.
It should be noted however that our analysis of mRNA structure
and stability has a number of drawbacks and is limited by the
centering of the variant nucleotide position within the queried
nucleotide sequence. Previously, De Smit and van Duin quanti-
tatively demonstrated the relationship between translational
efficiency and mRNA structure at the initiation site; an increase
in the stability corresponds to a decrease in initiation rate, which
was measured by expression levels of RNA bacteriophage MS2
gene [49]. This observation was further supported in a study
utilizing a synthetic library of 154 GFP gene variants expressed in
E. coli that varied randomly at synonymous sites [50] and more
recently in a genome wide association study in yeast [51].
However, in prokaryotes and lower eukaryotes mRNPs are less
abundant and thus the impact of the effects at the polynucleotide
level can be better seen and/or be more pronounced [48]. It
should be also mentioned that it has been suggested that after
translational initiation (particularly in higher eukaryotes), the
ribosome can, in most cases, locally destabilize secondary
structures and move along the message without any significant
delays [52], yet complex and stable structures close to the initation
site may be detrimental to elongation process [11]. Overall, GC
content of the mRNA, which may impact the stability of the
mRNA structure, was also reported to alter protein expression
levels in mammalian cells as measured using a GFP reporter
system [53]. In addition, Bartoszewski and colleagues recently
reported that a synonymous variant (in position 507) in the coding
region of the human CFTR may alter mRNA structure and reduce
translation rate and expression of CFTR, as compared to WT
protein in addition to the known variant in position 508 [54].
While the data at present are insufficient to draw a conclusion with
regard to the predicted structure of mRNA and protein expression
levels [55], our results suggest that analysis of the changes in
mRNA free energies associated with variants of interest bears
further investigation which may lead to their development as
predictive tools for protein expression levels.
To look at other possibilities we decided to explore a possible
relationship between ADAMTS13 expression levels and changes
in codon usage, a known mediator of protein expression,
associated with variants under investigation. We found a strong
correlation between intracellular ADAMTS13 levels and the
changes in codon usage as measured by RSCU (Figure 1D). This
strong correlation between in vitro and in silico data may enable us
to establish a number of predictive tools for future analysis of other
variants and their effects. However, more data would be required
in order to make such type of predictions truly reliable.
We further chose to look at ADAMT13 specific activity as
a measure of protein folding/conformation (Figure 3A). Fluoro-
genic FRETS-VWF73 substrate [56,57] was chosen to test
ADAMTS13 activity due to the following reasons: (i) It has been
reported in an international independent blind study that FRETS-
VWF73 is the most reproducible ADAMTS13 activity assay [58].
(ii) Data from Tripodi et al. suggests that inter-individual variation
between normal subjects is more pronounced during shorter
incubation times: therefore, initial rate of the specific activity by
FRETS-VWF73 was used here as a means of measuring
Table 2. Conservation of ADAMTS13 variants across species.
Base-pair position Amino-acid position Conservation score
354* 118 6
420* 140 3
1342 448 4
1423 475 5
1451 484 4
1716* 572 5
1852 618 1
2280* 760 3
2699 900 5
2910* 970 1
3097 1033 6
4221* 1407 7
*Synonymous ADAMTS13 variants.
Conservation scores were calculated using tools from the ConSeq server (http://
conseq.tau.ac.il/ver1.1/index.html). The conservation ranges from 1 (not
conserved) to 9 (most conserved).
doi:10.1371/journal.pone.0038864.t002
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we are not accounting for possible in vivo interactions between
ADAMTS13 variants and the full-length VWF. By eliminating the
complexity of confounding variables, such as substrate binding
affinity and cleavage, the ADAMTS13-mediated proteolysis could
be directly quantified for all twelve variants and WT.
Analysis of specific activity of non-synonymous 2699
ADAMTS13 variant vs. WT revealed significant differences in
KM and VMAX between the intracellular forms but no difference
between the extracellular forms (Figure 3B). Our hypothesis is that
intracellular non-synonymous variant 2699 consists of several
forms, some of them with conformation(s) that allow higher affinity
to the substrate and hence activity, but they could not pass the ER
quality control to be secreted [60–64]. Upon secretion, the WT
and the variant carry similar activity. Moreover, the observed
increases and decreases in activity of the polymorphic
ADAMTS13 variants examined in this study were quite in-
teresting considering the fact that these variants do not reside in
the active site. Therefore, the effects of these variants on the
function of ADAMTS13 may be exerted by way of altered
conformation between variants and WT. Limited trypsin digestion
demonstrate that the WT and variants have different trypsin
sensitivity possibly due to exposure of different trypsin sites e.g. the
non-synonymous 1852 variant showed reduced susceptibility to
trypsin as compared to WT protein (Figure 3C).
It is also interesting to note that many variants under discussion
are predicted to occur in beta-structures/their edges (Figure 4,
Table 1). In particular, non-synonymous variant 1852 results in
a substitution of Pro to Ala at the edge of a short 3-residue beta-
structure which is a part of an extended antiparallel beta-sheet,
forming beta-sheet sandwich (Figure 4). Beta-sheets, as a rule, are
thermodynamically more stable than alpha-helices and hence their
impact on overall protein folding/stability is greater. Therefore,
variants in beta-sheets are expected to produce greater impact on
protein folding [65]. Our analysis however didn’t reveal any
statistically significant association between the location of variants
and the residue conservation (Table 2). The exact reasons why
synonymous substitution of CCG to CCA encoding Pro118Pro
(synonymous variant 354) results in a substantial increase of
ADAMTS13 specific activity, while substitution of GGT to GGC
encoding Gly760Gly (synonymous variant 2280) did not, remain
unclear. Both synonymous variants Pro118Pro (variant 354) and
Gly760Gly (2280) were predicted to be located at the edges of the
beta-structures. Perhaps, CCG to CCA substitution may facilitate
cis-trans Pro118 isomerization and thus lead to an increased
ADAMTS13 specific activity.
In sum, we have demonstrated that non-synonymous and
synonymous variants can significantly alter both intracellular and
extracellular protein expression as well as protein activity.
Currently, there are only a handful of ex vivo studies focused on
ADAMTS13 variants, however to our knowledge there have been
no comprehensive reports detailing such an extensive array of
variants for mRNA and protein expression as well as protein
specific activity. Our results concur with a previous report by
Plaimauer et al. establishing that the expression of intracellular
non-synonymous variant 1852 is similar to WT but extracellular
expression is only 27% of WT (we report 28% of WT) [21].
Plaimauer et al. also reported the extracellular expression of non-
synonymous variant 1342 to be 95% of WT; similarly Kokame et
al. reported similar expression of non-synonymous variant 1342 as
compared to WT (although careful quantitation of the products
was not performed in this study) [20,21]. However, we found
a slightly larger decrease in the expression of ns1342 ADAMTS13
variant as compared to WT. Furthermore, Kokame et al., observed
that non-synonymous variant 1423 showed no change in
expression as compared to WT [20]. However, we detected
a 12% increase in extracellular expression as compared to WT for
non-synonymous variant 1423.
Other reports have investigated several of the ADAMTS13
variants studied here alone or in concert with additional variants,
however their results cannot be directly compared to the results
reported here due to differences in the expression systems and
methods used; yet, some valuable information can be extracted. In
a different system which examines the expression and function
72 h. post-transduction, Tao et al. used a synonymous 3097
ADAMTS13 variant as a positive control and observed equal
extracellular expression and VWF-cleavage activity compared to
WT ADAMTS13 in HeLa cells [23]. Interestingly, at the same
time, secreted WT ADAMTS13 was not expressed at levels
comparable to that of the synonymous variant 3097 during short-
term expression which might reflect the situation of clot formation
in vivo. In addition to these ex vivo studies, Schettert et al. reports an
association between the non-synonymous variant 2699 and
increased risk of death by an adverse cardiovascular event and
lower cholesterol levels, while no such association was found for
the 1852 variant [22]. The correlation between cardiovascular
events and expression and specific activity of individual variants
has yet to be determined. Therefore, the significant decrease in
expression of the non-synonymous variant 1852 and a lack of
adverse cardiovascular events in patients may suggest other
complex factors.
So, how do variants under study, particularly synonymous
variants, exert their effects (leading to altered protein conforma-
tion) without altering protein composition? One of the elements
that might influence protein folding is codon-usage bias. A co-
translational, sequential folding model which incorporates a folding
funnel characterized by conformation intermediates and an
eventual free energy minima ground-state conformation has been
suggested as a plausible hypothesis for in vivo protein folding [10].
Recent evidence has demonstrated that codon usage can fine-tune
this co-translational folding as the ribosome pauses at rare codons
or speeds up at common codons providing a delay or lack thereof
in the growth of the nascent polypeptide [19]. We hypothesize that
the conformational differences observed between synonymous
ADAMTS13 variants may result from the changes in codon usage
and corresponding ribosomal translation speeds. This change in
translation speed prompts a divergence from the WT folding
pathway and therefore might create a new protein conformation.
Statistical analysis revealed no inherent bias in our codon usage
tools (RSCU and log ratio) resulting from our choice of twelve
variants, compared to the RSCU and log ratio of all variants
within ADAMTS13. No correlation was found between the
DRSCU using genomic codon usages and the specific activity of
ADAMTS13 using the FRETS-VWF73 substrate. Extracellular
protein expression may be significantly influenced by variant-
induced conformational changes and this may explain an
additional lack of correlations between specific activity and in
silico analyses. This indeed suggests that codon usage plays an
important role in the protein activity implying that codon usage
affects the local rates of translation and thus protein folding and
specific activity.
In the last few years, the general belief that synonymous variants
are silent has been reevaluated due to the accumulation of data
suggesting that they can interfere with the mRNA structure, codon
usage and/or conformation of the resultant protein, thereby
possibly affecting its function. Moreover, many recombinant
proteins carry variants or common haplotypes with currently little
attention being paid to which haplotype is used in their
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are precise enough to distinguish between slight changes in protein
expression and activity levels. Therefore, we believe that these tests
and type of analysis may serve as useful tools to better understand
the effects of different variants in any target protein and may be
also used during the design and evaluation of therapeutic
recombinant proteins.
Materials and Methods
Cell Lines, Culture and Transfection Conditions
Human embryonic kidney cells (HEK293– ATCC; Manassas,
VA) were grown in Dulbecco’s Modified Eagle Medium (DMEM)
(Quality Biological, Inc; Gaithersburg, MD) with 1% glutamine
(Quality Biological, Inc), 1% penicillin- streptomycin (Hyclone;
Logan, UT) and 10% fetal bovine serum (Quality Biological, Inc)
at 37uC under humid conditions in 5% CO2. 1.2610
6 cells were
plated 24 hours (h.) before transfection in 2 mL growth medium in
6-well plates. Prior to transfection, DMEM was replaced with
1.6 mL Opti-MEM reduced Serum Medium (Invitrogen; Carls-
bad, CA). Cells were transfected with 1 mg of plasmid DNA using
6 mL of Lipofectamine 2000 (Invitrogen) in a total of 400 mL Opti-
MEM (Invitrogen). Independent transfections using the variant
and WT constructs were performed in triplicate for each variant.
A ratio of 1:9 and 1:5 eGFP: ADAMTS13 was used with the same
transfection conditions for co-transfection of eGFP and
ADAMTS13 in order to confirm similar transfection efficiencies
of the WT ADAMTS13 and each of the variants (data not shown).
Plasmids and Site Directed Mutagenesis
pcDNA4-ADAMTS13 (a gift from Dr. Evan Sadler; St. Louis,
MO), which carried a full-length ADAMTS13 (NM_139025)
cDNA conjugated to V5 and poly (His) tags was used as
a backbone for all constructs. Site directed mutagenesis (SDM)
was performed using the QuikChange Site Directed Mutagenesis
Kit (Stratagene; Cedar Creek, TX) to change this sequence to
WT. This sequence was then used as the WT reference standard
and as the backbone for all twelve variants containing constructs
produced via SDM. Bi-directional sequencing was used to confirm
that variants were successfully introduced. An empty vector was
used for mock-transfection control studies. All ADAMTS13
plasmids were purified using cesium chloride gradient (performed
by Lofstrand Labs Limited; Gaithersburg, MD) to obtain high
quality supercoiled plasmids. Plasmid expressing enhanced green
fluorescence protein (Clontech peGFP-C1, referred here as eGFP)
was used for co-transfection assays. All the variants investigated in
this study are described in Table 1.
Cell Harvest: Cell Lysate and Media Preparation
To detect minor changes in ADAMTS13 expression or
function, we chose to harvest cells 24 h. post–transfection because
ADAMTS13 expression and function are in a linear response
range. Cells and media were collected, cell lysates were prepared
and cell media was concentrated, as previously described [18,66].
Protein concentration was measured using Bio-Rad Protein Assay
according to the manufacturer’s instructions (Bio-Rad; New York,
NY) or by A280 using a NanoDrop 2000C (Thermo Scientific;
Wilmington, DE). Concentrated media and cell lysates were
aliquoted and stored at 280uC until further use. The following
controls were applied in order to assure similar condition between
different transfection experiments: (i) Only high quality, super-
coiled DNA plasmids were used for transfections, (ii) eGFP co-
transfections were carried out and flow cytometry was used to
determine equal transfection efficiencies, as specified below, (iii)
the exact same number of cells were plated for each transfection,
(iv) each study included a transfected WT plasmid for internal
comparison among variants transfected concurrently, and (v) each
study included a transfected empty plasmid, a negative control
which was used for expression and function studies.
RNA and qPCR Preparation
RNA was isolated (24 h. post-transfection) using RNeasy Plus
Mini Kit (Qiagen Sciences, Germantown, MD) following
manufacturer’s instructions. Reverse Transcription was carried
out as previously described [34]. Quantitative real time PCR
(qPCR) was done using the LightCycler RNA master SYBR
Green Kit and LightCycler 480 (Roche Applied Science,
Indianapolis, IN), using 1 ng of total RNA with an initial melting
cycle of 30 seconds (s) at 95uC followed by 40 cycles of 8 s at 95uC,
12 s at 58uC and 10 s at 72uC. ADAMTS13 was probed with 59-
tcacagccaacctcacctcg’39 (Forward (F)) and 59-ccgcacctgccggttac-39
(Reverse (R)) primers using GAPDH as a reference gene with
primers 59-tcgtggagtccactggcgtctt-39 (F) and 59-tggcagtgatggcatg-
gactgt-39 (R). Crossing Point (Cp) values were obtained and
presented in the DDCp method using WT as the comparative
control for each variant as previously described [67].
SDS-PAGE Immunoblotting
Samples were sonicated twice for 5 min., boiled in SDS
reducing buffer for 10 min. and then resolved by electrophoresis
in NuPAGE 7% Tris-Acetate gels (Invitrogen). Mouse anti-V5
primary antibody (Invitrogen) and goat anti-mouse HRP second-
ary antibody (Thermo Scientific) were used to detect the
transfected ADAMTS13. Antibody staining was detected using
Amersham ECL Western Blotting Detection Reagents (GE
Healthcare; Piscataway, NJ) on Hyblot CL Autoradiography film
(Denville Scientific, Inc.; Metuchen, NJ). Densitometry analysis of
band intensities was performed using ImageJ 1.42 q software
(http://rsbweb.nih.gov/ij/) or the 4000 MM Pro Image Station
(CareStream Health, Inc; Woodbridge, CT) with CareStream
software. The following controls, in addition to those specified
under cell harvest: cell lysate and media preparation subsection, were
applied in order to assure reproducibility between different
transfection experiments and exclude results due to method
variations: (i) samples for Western blotting were loaded per total
protein concentrations, (ii) a loading control to verify equal total
protein loading using anti-b-actin (Abcam, Inc.; Cambridge, MA)
or anti-GAPDH (Santa Cruz Biotechnologies; Santa Cruz, CA)
were used in lysate samples, (iii) purified recombinant
ADAMTS13 (rADAMTS13 - a gift from Dr. Friedrich Schei-
flinger of Baxter Innovations GmbH; Vienna, Austria) was used as
a control, (iv) immunoblot analysis of three independent transfec-
tions using the linear V5 epitope, was used to determine the
internal variation of the variants on the level of ADAMTS13.
eGFP co-transfections were performed and harvested 24 h. post-
transfection as described above. Cells were washed twice with PBS
and eGFP was detected in FL-1 to determine transfection
efficiencies between ADAMTS13 plasmid constructs that were
shown to be similar (e.g. the median arbitrary fluorescence units of
the empty pcDNA3.1 plasmid and synonymous variant 420 was
524.2 and 556.9, respectively).
Trypsin Digestion
ADAMTS13-cell lysates (1852 vs. WT) were diluted using
100 mM Tris-HCl (Fisher Scientific; Fair Lawn, NJ) and subjected
to trypsin digestion for 5 minutes (min.) at 37uC with increasing
concentrations of freshly made enzyme (Sigma-Aldrich; St. Louis,
MO) at the following concentrations ranges 0–0.0005 mg/mL.
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inhibitor (Sigma-Aldrich) and analyzed by immunoblotting as
described below. Half life of the protein was calculated using
GraphPad Prism software.
FRETS-VWF73 Activity Assay
Fluorogenic FRETS-VWF73 substrate (Peptides International;
Louisville, KY) was prepared and assayed according to manu-
facturer’s instructions and as previously described [66]. Fluores-
cence readings were taken at 3–5 min. intervals for 2 h. at 30uC
by the Infinite F5000 spectrophotometer (Tecan US; Durham,
NC). Equal total volume of media was assayed and normalized
according to immunoblot densitometry data. FRETS-VWF73 was
analyzed using the rate of ADAMTS13 activity as a change in
fluorescence per unit of protein per min. An expanded activity
assay was performed for the non-synonymous variant 2699 using
a range of FRETS-VWF73 substrate concentrations, 0, 2.5, 5.0
and 10 mM. The kinetics of ADAMTS13 protease activity were
obtained by plotting this specific activity of the enzyme as
a function of substrate concentration and a Michaelis-Menten plot
was generated using GraphPad Prism software.
Relative Synonymous Codon Usage
Relative Synonymous Codon Usage (RSCU) was calculated for
all variants in the coding region of ADAMTS13 as described by
Sharp and Li
RSCU~
xij
1
ni
P ni
j~1
xij
where xij is the number of occurrences of the j
th codon for the i
th
amino acid, which is encoded by ni synonymous codons [33,68].
Each variant was analyzed relative to both the codon frequency
within ADAMTS13 cDNA as well as the codon frequency within
the entire human genome using the Codon Usage Database
(http://www.kazusa.or.jp/codon/, last accessed 21 May 2010)
[69]. The ADAMTS13 constructs used here are under transcrip-
tional control of a CMV promoter, which was reported to have
a 2,500% increase in activity when compared to a human BL-3
promoter [70]. Comparison of the viral promoters SV40, EMC,
HBV and CMV (which all carry high activity compared to human
promoters) in an adeno-associated viral infection system revealed
significantly higher expression of Blood Coagulation Factor IX
under a CMV promoter [71]. Therefore, the massive increase in
ADAMTS13 under the CMV promoter compared to basal
ADAMTS13 expression levels would alter the various natural
tRNA concentrations within the cell by depleting more quickly
tRNAs that bind to highly used codons in ADAMTS13. In-
terestingly, the CG content of the coding region of WT
ADAMTS13 is 64.8%, while in the average, protein coding
sequence it is only about 46% [72]. Additionally, ,8.3% of all
amino acids in WT ADAMTS13 are prolines (118 prolines), while
prolines only make up 6.2% of amino acids in the human genome.
Thus, although it is typical to perform these analyses using the
complete human genomic codon frequencies, over-expression of
ADAMTS13 in the transient transfection system enacts a signifi-
cant change in codon usage within the cell. Therefore, both
RSCU and the log ratio of codon frequencies were calculated not
only using human genomic frequencies but also using ADAMTS13
cDNA codon usages to mimic the strain of such over-expression.
RSCU values were calculated for each variant using the variant
codon. At all variant locations, the DRSCU value was computed
between the variant and WT sequence.
Log Ratio of Codon Frequencies
The frequency of the given codon divided by the frequency of
all synonymous codons for the encoded amino acid was calculated
for each variant. A log ratio of this frequency analysis was
performed in order to assess differences between variant and WT.
At each variant location, the log ratio of the frequency of the
individual codon was calculated. Two different frequencies were
used in these calculations: (i). Derived from human WT
ADAMTS13 cDNA codon frequencies (ii). Derived from the
human Codon Usage Database [69]. For all calculations, a Dlog
ratio of codon frequency value of variant versus the WT was
calculated. A third method employed by Dos Reis et al. [73], was
not used in the current study because the tRNA adaptation index
does not take into account intercellular differences in tRNA
content, which is necessary to address the relation of tRNA
content to codon bias and translation speed.
mFold and KineFold Analysis of mRNA Minimum Free
Energy Structures
Using default parameters, short fragments of ADAMTS13 ORF
(25, 75, 151, and 399 nt in length) were analyzed by mFold’s
online server (http://mfold.rna.albany.edu/?q=mfold/RNA-
Folding-Form) as well as the KineFold online server (http://
kinefold.curie.fr/cgi-bin/form.pl); variants were centered within
these sequences [24,74]. To better understand the impact of
variants on the minimum free energy of mRNA structure we have
expanded the range of lengths to investigate. The most stable
structure in terms of Gibbs free energy (DG) was determined and
used for later analysis. Additionally, WT sequences of the same
lengths were queried and a delta-delta G (DDG) value was
established by subtracting the Gibbs free energy value of WT from
the variant. The DDG was plotted and used for correlation studies.
ADAMTS13 3-D Structure Prediction and Analysis: Comparative
modeling of the ADAMTS13 structure was performed using the
3D-PSSM algorithm developed by Kelley and Sternberg and
Swiss-Pdb Viewer V4.0.2 using 1D and 3D sequence profiles
coupled with secondary structure and solvation potential in-
formation. PSSM E-value (the score or ‘‘expectation value’’ of the
match; ‘‘% Certainty’’) was used to compare different model
structures and the structures with the lowest E-value were chosen
for further analysis [35]. Two model fragments/structures
comprising ADAMTS13 residues 77–470 and 674–1254 (out of
the 1427 total residues) were built with the help of PyMOL v0.98
and/or Swiss-Pdb Viewer V4.0.2 and the amino acids encoded by
the codons/variants under investigation (whenever it was possible)
were visualized (van der Waals’ radii of the side chains were
shown). ADAMT13 fragment (comprising residues 287–682),
whose structure was solved by X-Ray crystallography (PDB ID
3GHM) was also visualized using Swiss-Pdb Viewer V4.0.2 and
the amino acids encoded by the codons/variants under in-
vestigation in this region (namely Gln448, Pro475, Arg484,
Thr572, Pro618) were also visualized (van der Waals’ radii of
the side chains were shown).
Variant Conservation
Using the ConSeq server (http://conseq.tau.ac.il/ver1.1/index.
html), the conservation of each individual variant was calculated
[75,76]. The conservation ranges from 1 (not conserved) to 9 (most
conserved) and based on a multiple sequence alignment of 50
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uniprot.org/, last accessed 7 June 2011).
Statistical Analysis
The mean ADAMTS13 mRNA transcript level, intracellular &
extracellular expression levels, and specific activity for the variants
and the wild-type were compared using 2-sided t tests for
independent samples, and a p-value less than.05 was considered
to be of statistical significance. We performed correlation analysis
using ex vivo and computational data. We first obtained compu-
tational data for variants and WT ADAMTS13 mRNA/protein.
The Spearman’s correlation coefficient between in silico and ex vivo
data was then computed. Finally, we performed linear regression
analysis for highly correlated cases where the correlation was
statistically significant at or below 5% using ordinary least squares
method. The statistical significance of DRSCU and Dlog ratio
scores for our set of variants was evaluated by assigning a MAD
score (robust Z-score) to each parameter. DRSCU and Dlog ratio
for all variants within the coding region of ADAMTS13 were
calculated based on data given the NCBI dbSNP database (http://
www.ncbi.nlm.nih.gov/snp, last accessed 24 October 2011). Since
the distribution of DRSCU and Dlog ratio for all variants within
the coding region of ADAMTS13 cannot simply assumed to be
normal, we used the MAD score as a more robust estimate of
outliers. All DRSCU and Dlog ratio scores for our set of variants
had |MAD score| ,3 i.e. they fall within the range of median
63MAD of the distribution of all variants within ADAMTS13.
Further, Spearman’s correlation matrix was computed for in
silico data (correlation $0.6 or #20.6; P,0.05) and ex vivo data in
order to determine if highly correlating sets of computational data
could possibly provide explanation for ex vivo data. We also looked
at correlation of ex vivo data between themselves. Additionally,
a linear regression analysis was performed for all the above cases to
ensure that obvious outliers that would skew the correlation
coefficient were not present.
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